The global demand for Shigella Infection Treatment Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Shigella infection is an intestinal disease caused by a class of bacteria called shigella. The main symptom of shigella infection is diarrhoea, which often is bloody. The bacteria enter into the body through contaminated food or by drinking or swimming in contaminated water. The infection is treated with drug medication. Medications include antibiotics to eliminate the bacteria from the digestive tract. Drug options include powerful antibiotic medications, such as azithromycin (Zithromax), ciprofloxacin (Cipro), sulfamethoxazole/trimethoprim (Bactrim).
Global cases are estimated to be 164.7 million per year, 98% of which occur in developing countries. 1.1 million falls for death, about 61% of all deaths attributable to shigellosis involved children younger than 5 years. The prevalence in developing countries is 20 times greater than that in developed countries. Shigellosis occurs predominantly in developing countries due to overcrowding and poor sanitation. Low awareness among people living in developing nations and inadequate control with the existing prevention and drug treatment measures is giving a push to design new strategies for awareness and treatment development. Innovative strategies, including the development of vaccines against the most common serotypes, could provide substantial benefits. There is room for optimism as advances in biotechnology have enabled the development of a new generation of candidate vaccines that show great promise for the prevention of Shigella infection. Successful outcomes will lead to increased growth of the market.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of shigella infection treatment.
The entire shigella infection treatment market has been sub-categorized into species type, drug class, and distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Species Type
By Drug Class
- Shigella Sonnei
- Shigella Flexneri
- Shigella Boydii
- Shigella Dysenteriae
By Distribution Channel
- Beta-lactams Antibiotics
- Third-generation Cephalosporins
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
This section covers regional segmentation which accentuates on current and future demand for shigella infection treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Shigella Infection Treatment Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the shigella infection treatment market include Emergent BioSolutions, Inc., Pfizer, Inc., LimmaTech Biologics AG, Zydus Cadila, Aurobindo Pharma. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.